PANOPTES
Peptide-based Nanoparticles as Ocular Drug Delivery Vehicles
| Coordinatore | UNIVERSITY OF DURHAM
Organization address
address: STOCKTON ROAD THE PALATINE CENTRE contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.panoptesfp7.eu/ |
| Totale costo | 5˙453˙873 € |
| EC contributo | 3˙900˙000 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2009-SMALL-3 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-11-01 - 2014-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF DURHAM
Organization address
address: STOCKTON ROAD THE PALATINE CENTRE contact info |
UK (DURHAM) | coordinator | 787˙312.55 |
| 2 |
UNIVERSIDAD COMPLUTENSE DE MADRID
Organization address
address: AVENIDA DE SENECA 2 contact info |
ES (MADRID) | participant | 759˙368.00 |
| 3 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 742˙400.00 |
| 4 |
DSM Ahead BV
Organization address
address: Poststraat 1 contact info |
NL (Sittard) | participant | 587˙050.50 |
| 5 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 566˙547.20 |
| 6 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 457˙321.75 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project will develop methodology for the manufacture of novel peptide-based nanoparticles and nanocapsules to satisfy an unmet clinical need: sustained drug delivery to the posterior segment of the eye. The proposed consortium brings together internationally leading groups in self-assembling polypeptide nanoparticle and nanocapsule preparation by chemical (Durham) and genetic (Nijmegen) approaches, drug loading and in vitro release studies (Helsinki & Madrid), in vitro and in vivo assessment of nanoparticle biocompatibility and functionality (Helsinki, Madrid & Tübingen) and polymer synthesis, processing and industrial validation of manufacturing processes (DSM). Polyester micro- and nanoparticles that have been proposed for ocular drug delivery have several major drawbacks: acidic degradation products cause inflammation; drug release is difficult to control; and peptides and proteins are difficult to encapsulate. A platform of novel, peptide-based nanomaterials, formed through bio-inspired self-assembly processes, will be developed to overcome these problems. Peptide-based materials have a number of attractive features: biodegradation gives non-inflammatory products; self-assembly occurs under mild conditions; they possess a rich chemical diversity; they are defined at the sequence level. Polypeptides and peptide hybrid materials will be processed into nanoparticles, polymeric vesicles (polymersomes) and nanocapsules. These biodegradable and biocompatible materials will be used as containers for the loading, controlled release and cellular delivery of therapeutic molecules. The consortium therefore will enable the industrial manufacture of as-yet unobtainable, high value nanotechnology-based products utilising intrinisically low-energy demand nanobiotechnological phenomena. These will produce a step change improvement in the quality of products for sustained drug delivery to the posterior segment of the eye, enhancing the competitiveness of European industry.'
Introduzione (Teaser)
New methods of administering drugs to treat eye diseases are being developed by EU researchers. These have an essential role to play in overcoming the eye's formidable defences against foreign substances.
Descrizione progetto (Article)
The eye has two main anatomical segments: the anterior segment and the posterior segment. Diseases affecting the latter are responsible for causing visual impairment and blindness. They include age-related macular degeneration; currently, around 6.5 million Europeans suffer from this eye or ocular condition.
Within the past decade, drug delivery to the eye has become important for treating several vision-threatening eye disorders. However, the anatomy, physiology, and biochemistry of the eye make it resistant to foreign substances. A new approach to bring about sustained drug delivery to the back part of the eye is urgently required.
To meet this unmet clinical demand, a European consortium was established bringing together five university research groups and a life sciences company. Together they formed the EU-funded 'Peptide-based nanoparticles as ocular drug delivery vehicles' (Panoptes) project. Peptides are short chains of amino acids.
The Panoptes project's aim is to develop ways to manufacture novel peptide-based microparticles, nanoparticles and nanocapsules to deliver drugs where they are needed in the eye. These biodegradable and biocompatible materials will be used as containers for the loading, controlled release and cellular delivery of therapeutic molecules.
To date, the project has produced polypeptides by chemical methods and through protein engineering. Initial studies have been performed and methods for assessing the drug loading and release characteristics have been validated. In addition, protocols have now been established to test injectable formulations of nanoparticles as new drug delivery agents.
Research work is continuing in the Panoptes project. If successful, the research will produce a step-change improvement in sustained drug delivery to the posterior segment of the eye. At the same time, it will enhance both the care of Europe's patients and the competitiveness of European industry.